|Mr. Michael Richard Feldschuh||Chairman, Pres & CEO||100k||N/A||1969|
|Mr. Jonathan Adam Feldschuh||Chief Scientific Officer & Director||127.92k||N/A||1965|
|Mr. Robert J. Michel M.B.A., CPA, CPA||CFO, Chief Compliance Officer & Corp. Sec.||N/A||N/A||1957|
|Ms. Kathryn A. Kornafel||VP of Marketing & Commercial Devel.||N/A||N/A||N/A|
|Mr. Guido Manzo||VP of Sales||N/A||N/A||N/A|
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Daxor Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.